Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: Data from a randomized controlled trial

American Journal of Geriatric Psychiatry

Volumn 22, Issue 10, 2014, Pages 971-979

  Garfield, Lauren D ^a   Dixon, David ^a   Nowotny, Petra ^a   Lotrich, Francis E ^b   Pollock, Bruce G ^c   Kristjansson, Sean D ^a   Doré, Peter M ^a   Lenze, Eric J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

SSRI side effects serotonin pharmacogenetic older adults

Indexed keywords

ESCITALOPRAM; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; CITALOPRAM;

5 HTTLPR GENE; ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASTHENIA; DATA ANALYSIS; DIARRHEA; DYSTONIA; FATIGUE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HTR1A GENE; HTR2A GENE; HUMAN; LASSITUDE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; PHARMACOGENETICS; PHOTOSENSITIVITY; POLYDIPSIA; POLYURIA; PROMOTER REGION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP TIME; TREMOR; UKU SIDE EFFECT RATING SCALE; XEROSTOMIA; ANXIETY DISORDERS; BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENETICS; MIDDLE AGED;

AGED; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84908077465     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.07.003     Document Type: Article

References (32)

1. L.J. Pratt, D.J. Brody, and Q. Gu Antidepressant use in persons aged 12 and older: United States, 2005-2008 2011 National Center for Health Statistics Hyattsville, MD
2. A.F. Schatzberg Safety and tolerability of antidepressants: weighing the impact in treatment decisions J Clin Psychiatry 68 2007 26 34
3. G. Gartlehner, R.A. Hansen, and T.S. Carey Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis Int Clin Psychopharmacol 20 2005 59 69
4. E. Cascade, A.H. Kalali, and S.H. Kennedy Real-world data on SSRI antidepressant side effects Psychiatry (Edgemont) 6 2009 16 18
5. M. Mamdani, M. Rapoport, and K.I. Shulman Mental health-related drug utilization among older adults: prevalence, trends, and costs Am J Geriatr Psychiatry 13 2005 892 900
6. M. Olfson, and S.C. Marcus National patterns in antidepressant medication treatment Arch Gen Psychiatry 66 2009 848 856
7. B.G. Pollock Adverse reactions of antidepressants in elderly patients J Clin Psychiatry 60 suppl 20 1999 4 8
8. T.L. Mark, V.N. Joish, and J.W. Hay Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs Am J Geriatr Psychiatry 19 2011 211 221
9. A. Serretti, and L. Mandelli Antidepressants and body weight: a comprehensive review and meta-analysis J Clin Psychiatry 71 2010 1259 1272
10. E.J. Lenze, D. Dixon, and P. Nowotny Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors Int J Neuropsychopharmacol 16 2013 279 288
11. B. Drueke, J. Baetz, and M. Boecker Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study Psychopharmacology (Berl) 207 2009 213 223
12. J.J. Gagne, A.R. Patrick, and H. Mogun Antidepressants and fracture risk in older adults: a comparative safety analysis Clin Pharmacol Therap 89 2011 880 887
13. J.H. Joo, E.J. Lenze, and B.H. Mulsant Risk factors for falls during treatment of late-life depression J Clin Psychiatry 63 2002 936 941
14. F. Laghrissi-Thode, B.G. Pollock, and M.C. Miller Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients Psychopharmacol Bull 31 1995 659 663
15. H.D. Anderson, W.D. Pace, and A.M. Libby Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study Clin Ther 34 2012 113 123
16. F. Lotrich, R. Bies, and M. Muldoon Neuroendocrine response to intravenous ncitalopram in healthy control subjects: Pharmacokinetic influences Psychopharmacology 178 2005 268 275
17. F.E. Lotrich, and B.G. Pollock Candidate genes for antidepressant response to selective serotonin reuptake inhibitors Neuropsychiatr Dis Treat 1 2005 17 35
18. E.J. Lenze, B.L. Rollman, and M.K. Shear Escitalopram for older adults with generalized anxiety disorder: a placebo-controlled trial JAMA 301 2009 296 303
19. M.B. First, R.L. Spitzer, and M. Gibbon Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet Washington, DC, American Psychiatric Press, 1996
20. M. Hamilton The assessment of anxiety states by rating Br J Med Psychol 32 1959 50 55
21. O. Lingjaerde, U.G. Ahlfors, and P. Bech The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 334 1987 1 100
22. J.R. Wendland, B.J. Martin, and M.R. Kruse Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531 Mol Psychiatry 11 2006 224 226
23. J.P. Foglia, D. Sorisio, and M. Kirshner Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection J Chromatogr B Biomed Sci Appl 693 1997 147 151
24. S.L. Beal, and L.B. Sheiner NONMEM Users Guides San Francisco, CA 1992
25. Y. Jin, B.G. Pollock, and E. Frank The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram J Clin Pharmacol 49 2009 176 184
26. K.-Y. Liang, and S.L. Zeger Longitudinal data analysis using generalized linear models Biometrika 73 1986 13 22
27. S.H. Lipsitz, K. Kim, and L. Zhao Analysis of repeated categorical data using generalized estimating equations Stat Med 13 1994 1149 1163
28. M.E. Miller, C.S. Davis, and J.R. Landis The analysis of longitudinal polytomous data: generalized estimating equations and connections with weighted least squares Biometrics 49 1993 1033 1044
29. K.M. Smits, L.J. Smits, and F.P. Peeters Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors Int Clin Psychopharmacol 22 2007 137 143
30. R. Paternoster, R. Brame, and P. Mazerolle Using the correct statistical test for the equality of regression coefficients Criminology 36 1998 859 866
31. M. Berger, J.A. Gray, and B.R. Roth The expanded biology of serotonin Annu Rev Med 60 2009 355 366
32. M. Kato, and A. Serretti Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder Mol Psychiatry 15 2010 473 500